| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
|
J Natl Cancer Inst
|
1993
|
38.99
|
|
2
|
A phase 2 study of bortezomib in relapsed, refractory myeloma.
|
N Engl J Med
|
2003
|
16.11
|
|
3
|
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
|
Br J Haematol
|
2003
|
14.41
|
|
4
|
Cancer statistics, 2000.
|
CA Cancer J Clin
|
2000
|
12.32
|
|
5
|
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
|
Br J Haematol
|
1998
|
10.77
|
|
6
|
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
|
J Clin Oncol
|
2002
|
4.69
|
|
7
|
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
|
Lancet Oncol
|
2010
|
4.10
|
|
8
|
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
|
Br J Haematol
|
2004
|
3.49
|
|
9
|
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
|
J Clin Oncol
|
1998
|
3.41
|
|
10
|
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
|
J Clin Oncol
|
2002
|
2.63
|
|
11
|
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
|
JAMA
|
1969
|
2.56
|
|
12
|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
|
Blood
|
2006
|
2.51
|
|
13
|
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
|
Lancet
|
1992
|
2.08
|
|
14
|
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
|
J Clin Oncol
|
2003
|
1.87
|
|
15
|
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
|
Blood
|
2015
|
1.45
|
|
16
|
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
|
Blood
|
2002
|
1.44
|
|
17
|
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.
|
Haematologica
|
2013
|
1.26
|
|
18
|
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.
|
Leukemia
|
2013
|
1.20
|
|
19
|
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
|
Blood
|
2012
|
1.19
|
|
20
|
Thalidomide--a revival story.
|
N Engl J Med
|
1999
|
1.13
|
|
21
|
Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.
|
J Clin Oncol
|
1983
|
1.04
|
|
22
|
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
|
Blood
|
2011
|
1.03
|
|
23
|
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
|
Blood
|
2002
|
1.02
|
|
24
|
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
|
Cancer
|
1997
|
0.98
|
|
25
|
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life.
|
Br J Haematol
|
1999
|
0.96
|
|
26
|
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
|
Blood
|
2014
|
0.96
|
|
27
|
A controlled trial of urethane treatment in multiple myeloma.
|
Blood
|
1966
|
0.95
|
|
28
|
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
|
J Clin Oncol
|
1991
|
0.93
|
|
29
|
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
|
Br J Haematol
|
2013
|
0.91
|
|
30
|
Genomic analysis of high-risk smoldering multiple myeloma.
|
Haematologica
|
2012
|
0.90
|
|
31
|
Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
|
J Clin Oncol
|
1998
|
0.89
|
|
32
|
Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
|
Eur J Haematol
|
1992
|
0.83
|
|
33
|
Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients.
|
Haematologica
|
2010
|
0.82
|
|
34
|
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
|
J Clin Oncol
|
1993
|
0.81
|
|
35
|
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
|
Haematologica
|
2014
|
0.79
|
|
36
|
Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?
|
Med Oncol
|
2000
|
0.78
|
|
37
|
Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
|
Semin Hematol
|
2003
|
0.75
|
|
38
|
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.
|
Leuk Res Rep
|
2015
|
0.75
|
|
39
|
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
|
Ann Hematol
|
2016
|
0.75
|